v3.25.2
Segment Information (Tables)
12 Months Ended
May 31, 2025
DiamiR Biosciences Corp. [Member]  
Segment Information [Line Items]  
Schedule of Segment Revenue and Expenses

Segment revenue and expenses are as follows in the years ended May 31, 2025 and 2024.

 

2025

 

2024

Revenue

 

$

631,729

 

 

$

1,319,531

 

Research and development

 

 

 

 

 

 

 

 

Salaries and benefits

 

 

449,344

 

 

 

692,875

 

Consultants and contractors

 

 

176,935

 

 

 

278,837

 

Stock based compensation

 

 

24,312

 

 

 

182,912

 

Other R&D

 

 

 

 

 

2,236

 

Total research and development

 

 

650,591

 

 

 

1,156,860

 

General and administrative

 

 

 

 

 

 

 

 

Salaries and benefits

 

 

105,761

 

 

 

117,883

 

Consultants and contractors

 

 

213,509

 

 

 

292,234

 

Stock based compensation

 

 

 

 

 

11,934

 

Patents

 

 

44,363

 

 

 

30,167

 

Depreciation

 

 

20,828

 

 

 

20,052

 

Offering costs

 

 

150,526

 

 

 

 

Rent and facilities

 

 

53,483

 

 

 

55,600

 

Other

 

 

35,918

 

 

 

86,204

 

Total general and administrative

 

 

624,388

 

 

 

614,074

 

Interest expense

 

 

82,046

 

 

 

48,599

 

Income taxes

 

 

17,939

 

 

 

114,403

 

Net loss

 

$

(743,235

)

 

$

(614,405

)